How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers-Reference-Cited by-同舟云学术

How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers

Published:2019-02-04 Issue:4 Volume:35 Page:623-629
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Van Tine Brian A.¹,Trent Jonathan C.²

Affiliation:

1. Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA;

2. Division of Hematology and Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2019.1570768

Reference34 articles.

1. Management of Advanced Adult Soft Tissue Sarcoma

2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): soft tissue sarcoma (Version 1.2019). December 19, 2018. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed January 29, 2019.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene expression-based prediction of pazopanib efficacy in sarcoma;European Journal of Cancer;2022-09

2. Effects of human serum albumin glycation on the interaction with the tyrosine kinase inhibitor pazopanib unveiled by multi-spectroscopic and bioinformatic tools;Journal of Molecular Liquids;2021-10

3. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy;European Journal of Cancer;2020-09

4. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort;Journal of Oncology Pharmacy Practice;2020-02-17